Tradestie Institutional Equity Comparison Engine
ABSI vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Overall Edge
DMAC Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABSI trades at N/M Forward P/E with -9108.3% operating margin (-19.6% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABSI sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ABSI N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner
DMAC
Op Margin -9108.3% vs 0.0% ยท YoY -19.6% vs +0.0%
Momentum & Technical Winner
DMAC
1Y +192.6% vs +55.3% ยท 52W Pos 53% vs 55%
Options & Structure Winner
DMAC
BREAKDOWN (15th %ile IV) vs SURGE (14th %ile IV)
ABSI
NASDAQ
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.72
-8.58% 1D
Market Cap
$1.6B
1M Return
-6.36%
1Y Return
+192.61%
Forward P/E
N/M
Unified AI Score
41.2 / 100
SELL
Tech 30.0
Fund 51.0
Flow 71.0
Mom 60.0
DMAC
NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap
$503.1M
1M Return
+11.16%
1Y Return
+55.26%
Forward P/E
N/M
Unified AI Score
46.3 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ABSI +192.61%
DMAC +55.26%
Spread: +137.35 pp (ABSI Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABSI Revenue | DMAC Revenue | ABSI Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -1352.2% | DMAC |
| FY2020 | $0M | N/A | -278.3% | N/A | ABSI |
| FY2021 | $0M | N/A | -1573.4% | N/A | ABSI |
| FY2022 | $10M | N/A | -1857.5% | N/A | ABSI |
| FY2023 | $10M | N/A | -2020.2% | N/A | ABSI |
| FY2024 | $0M | N/A | -2401.6% | N/A | ABSI |
| FY2025 | $0M | N/A | -4297.0% | N/A | ABSI |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABSI | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.6B | $503.1M | Larger Scale | ABSI |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -19.6% | +0.0% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | -9108.3% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -58.6% | -114.6% | Higher ROE | ABSI |
| 52-Week Range Position Momentum | 53% ($2โ$13) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 3.31ฮฒ ยท 126% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | DMAC |
| Unified Institutional Score Composite Signal | 41.2 / 100 (SELL) | 46.3 / 100 (HOLD) | Higher Composite | DMAC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ABSI vs DMAC Buy Guide
ABSI
BREAKDOWN
97d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
15th %ile
IV Regime
Compressed (<25th %ile)
DMAC
SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ABSI nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.